12:00 AM
 | 
Sep 07, 1999
 |  BC Week In Review  |  Company News  |  Deals

Isis, Boehringer Ingelheim deal

ISIP reacquired from partner Boehringer Ingelheim rights to its ISIS 2302 antisense compound against intercellular adhesion molecule-1 ( ICAM-1), which is in Phase III testing to...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >